TKG Advisors LLC Purchases New Shares in Gilead Sciences, Inc. $GILD

TKG Advisors LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 46,480 shares of the biopharmaceutical company’s stock, valued at approximately $5,153,000. Gilead Sciences accounts for approximately 2.3% of TKG Advisors LLC’s investment portfolio, making the stock its 16th biggest position.

Other large investors have also made changes to their positions in the company. Activest Wealth Management boosted its holdings in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. GoalVest Advisory LLC boosted its holdings in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. Harbor Asset Planning Inc. acquired a new position in shares of Gilead Sciences in the second quarter valued at approximately $27,000. Putney Financial Group LLC boosted its holdings in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the period. Finally, Colonial Trust Advisors raised its holdings in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 213 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a research report on Tuesday, August 19th. Citigroup boosted their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $133.00 price objective on shares of Gilead Sciences in a research report on Friday, October 31st. Finally, Truist Financial reaffirmed a “buy” rating and set a $145.00 target price (up previously from $127.00) on shares of Gilead Sciences in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $125.08.

Gilead Sciences Price Performance

GILD opened at $123.00 on Wednesday. Gilead Sciences, Inc. has a 12-month low of $86.08 and a 12-month high of $124.61. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a fifty day simple moving average of $115.98 and a two-hundred day simple moving average of $111.92. The company has a market cap of $152.62 billion, a price-to-earnings ratio of 24.50, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the previous year, the company posted $2.02 earnings per share. Gilead Sciences’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $354,240.00. Following the sale, the insider directly owned 110,193 shares in the company, valued at approximately $13,011,589.44. The trade was a 2.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 71,500 shares of company stock valued at $8,336,040 over the last ninety days. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.